<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291538</url>
  </required_header>
  <id_info>
    <org_study_id>BRD/05/9-B</org_study_id>
    <nct_id>NCT00291538</nct_id>
  </id_info>
  <brief_title>Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma</brief_title>
  <official_title>Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <brief_summary>
    <textblock>
      In this open-label randomised phase I trial, bortezomib will be administrated to 2 groups of&#xD;
      10 patients with MM who have inclusion criteria use the extended 2nd line indication, either&#xD;
      intravenously (group 1 = 10 patients) or subcutaneously (group 2 = 10 patients). The schedule&#xD;
      of administration of bortezomib will be the following : 1.3 mg per square meter of&#xD;
      body-surface area twice weekly for 2 weeks, followed by 1 week without treatment, for up to&#xD;
      eight cycles, either IV (group 1) or SC (group 2).&#xD;
&#xD;
      The primary objective is to characterize the pharmacokinetics of the 2 routes of&#xD;
      administration.&#xD;
&#xD;
      The secondary objectives are to characterize the pharmacodynamics (20S proteasome inhibition&#xD;
      in whole blood), toxicity, including cardiac safety, and efficacy of the 2 routes of&#xD;
      administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>characterize the pharmacokinetics of the 2 routes of administration.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>characterize the pharmacodynamics (20S proteasome inhibition in whole blood),</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity, including cardiac safety,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy of the 2 routes of administration.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of MM according to the SWOG criteria (annex I)&#xD;
&#xD;
          -  symptomatic MM stage II or III according to Durie-Salmon staging system (annex II) or&#xD;
             stage I with one symptomatic osteolytic lesion&#xD;
&#xD;
          -  with progressive disease after at least one prior therapy and who have already&#xD;
             undergone or are unsuitable for bone marrow transplantation&#xD;
&#xD;
          -  with measurable levels of paraprotein in the serum (&gt; 1g/dl) or in the urine (&gt;&#xD;
             0.2g/24h)&#xD;
&#xD;
          -  age &lt; 75 years&#xD;
&#xD;
          -  able to understand and to given an informed consent&#xD;
&#xD;
          -  male, female without childbearing potential or negative urine pregnancy test within 72&#xD;
             hours prior to beginning the treatment. Women of childbearing potential must be&#xD;
             following adequate contraceptive measures. Men must agree to use an acceptable method&#xD;
             of contraception (for themselves or female partners) for the duration of the study&#xD;
&#xD;
          -  no active systemic infection. In the presence of any active systemic infection,&#xD;
             adequate broad-spectrum or organism-specific antibiotic coverage must be administered.&#xD;
             Patients must be afebrile with stable vital signs while receiving antibiotics for at&#xD;
             least 48 hours prior to beginning the treatment with Bortezomib.&#xD;
&#xD;
          -  Each subject will weigh ³50 kg and have a body mass index (BMI) of £30 kg/m2 (see&#xD;
             annex V for BMI formula).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  life expectancy &lt; 2 months&#xD;
&#xD;
          -  ECOG performance status &gt; 2 (annex III)&#xD;
&#xD;
          -  proven amyloidosis&#xD;
&#xD;
          -  positive HIV serology&#xD;
&#xD;
          -  antecedents of severe psychiatric disease&#xD;
&#xD;
          -  &gt; NCI grade 2 peripheral neuropathy (Annex IV)&#xD;
&#xD;
          -  History of clinically relevant cardiac disease, including prior myocardial infarction,&#xD;
             prior or existing heart failure, existing uncontrolled angina or clinically&#xD;
             significant pericardial disease Evidence of arrhythmia, 2nd degree or greater AV block&#xD;
             or prolonged QTc interval (&gt;0.45 seconds in males, &gt;0.47 seconds in females) on&#xD;
             screening ECG&#xD;
&#xD;
          -  serum biochemical values as follow&#xD;
&#xD;
          -  creatinine level &gt; 200mmol/l&#xD;
&#xD;
          -  bilirubin, transaminases or gGT &gt; 3 the upper normal limit&#xD;
&#xD;
          -  potassium, calcium or magnesium outside of upper or lower normal limits&#xD;
&#xD;
          -  haematology values as follow&#xD;
&#xD;
          -  platelet &lt; 70x 109 /L within 14 days of enrollment&#xD;
&#xD;
          -  absolute neutrophil count &lt;1.0 x 109/L within 14 days of enrolment&#xD;
&#xD;
          -  concomitant use of drugs able to modify QTc interval within 1 week prior to the first&#xD;
             dose of bortezomib and during Cycle 1 (Annex VI)&#xD;
&#xD;
          -  concomitant use of potent inhibitors or inducers of the cytochrome P450 (CYP) enzymes&#xD;
             3A and 2C19 within 1 week prior to the first dose of bortezomib and during Cycle 1&#xD;
             (see annex VII list of representative drugs).&#xD;
&#xD;
          -  use of any experimental drugs within 30 days of baseline&#xD;
&#xD;
          -  hypersensitivity to bortezomib, boron, or mannitol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc HAROUSSEAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes UH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lille UH</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nancy UH</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes UH</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>February 10, 2006</study_first_submitted>
  <study_first_submitted_qc>February 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2006</study_first_posted>
  <last_update_submitted>February 3, 2009</last_update_submitted>
  <last_update_submitted_qc>February 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

